Related references
Note: Only part of the references are listed.YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis
Bo-Kuan Wu et al.
NATURE GENETICS (2022)
Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1
Xuewei Bai et al.
HEPATOLOGY (2021)
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)
Mairead G. McNamara et al.
ONCOLOGIST (2021)
In Regard to A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)
Angela Dalia Ricci et al.
ONCOLOGIST (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
The multifaceted contribution of a-ketoglutarate to tumor progression: An opportunity to exploit?
Houda Abla et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
Parker L. Sulkowski et al.
NATURE (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer
Chengheng Liao et al.
CANCER DISCOVERY (2020)
Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis
Zhen Cai et al.
MOLECULAR CELL (2020)
2-Oxoglutarate-dependent dioxygenases in cancer
Julie-Aurore Losman et al.
NATURE REVIEWS CANCER (2020)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis
Larissa J. Vos et al.
JCO PRECISION ONCOLOGY (2019)
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation
Chiung-Kuei Huang et al.
CANCER LETTERS (2018)
IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
Mohammed Khurshed et al.
FASEB JOURNAL (2018)
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
Sarah P. Blagden et al.
BRITISH JOURNAL OF CANCER (2018)
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Apurva Jain et al.
JCO PRECISION ONCOLOGY (2018)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
Molecular Bases of Chemoresistance in Cholangiocarcinoma
Jose J. G. Marin et al.
CURRENT DRUG TARGETS (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
Molecular mechanisms for tumour resistance to chemotherapy
Shu-Ting Pan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice
Selvi Durmus et al.
DRUG RESISTANCE UPDATES (2016)
Aspartate β-Hydroxylase Modulates Cellular Senescence Through Glycogen Synthase Kinase 3β in Hepatocellular Carcinoma
Yoshifumi Iwagami et al.
HEPATOLOGY (2016)
Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression
Chiung-Kuei Huang et al.
PLOS ONE (2016)
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
Pu Wang et al.
CELL REPORTS (2015)
Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease
E. Rodriguez-Gallego et al.
INTERNATIONAL JOURNAL OF OBESITY (2015)
Chemotherapy induced DNA damage response Convergence of drugs and pathways
Derek Woods et al.
CANCER BIOLOGY & THERAPY (2013)
Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis
Chiung-Kuei Huang et al.
HEPATOLOGY (2013)
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers
Waraporn Chan-on et al.
NATURE GENETICS (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
DNA Damage Repair Pathways in Cancer Stem Cells
Marcello Maugeri-Sacca et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
γH2AX: a sensitive molecular marker of DNA damage and repair
L-J Mah et al.
LEUKEMIA (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
Suee Lee et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas
S. Rau et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
A novel Patient-like model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines
Alphonse E. Sirica et al.
HEPATOLOGY (2008)
TopBP1 activates the ATR-ATRIP complex
A Kumagai et al.
CELL (2006)
The comet assay: a method to measure DNA damage in individual cells
Peggy L. Olive et al.
NATURE PROTOCOLS (2006)
ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex
JH Lee et al.
SCIENCE (2005)
The MRN complex: coordinating and mediating the response to broken chromosomes
M van den Bosch et al.
EMBO REPORTS (2003)
Share Paper
